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Study Group 
A fluconazole 25 IJg disk diffusion test was used to 
test 2230 consecutively isolated Candida strains 
from 42 different hospital laboratories in 23 coun- 
tries. Ninety seven percent of 1634 Candida atbi- 
cans isolates and 83.4% of 596 non-Candida albi- 
cans isolates were susceptible to fluconazole, 
applying the proposed breakpoints (_>26 mm for 
susceptible strains and 18-25 mm for dose- 
dependent susceptible strains). This is the first hos- 
pital laboratory study to evaluate a large number 
and wide range of sequential Candida isolates 
from patients with all types of hospital infections. 
The fluconazole disk diffusion test appears to be a 
low-cost, reproducible, and accurate means of 
assessing the in vitro susceptibility of Candida iso- 
lates. 
The lack of a reliable standardised antifungal sus- 
ceptibility test method has complicated the inter- 
pretation of many study reports until recently. 
However, significant progress has been made in 
the past ten years in developing more practical 
methods for the susceptibility esting of yeasts. 
Efforts of the National Committee for Clinical 
Laboratory Standards (NCCLS) have focused on 
developing a reference macrobroth minimum in- 
hibitory concentration (MIC) method for testing 
yeast species (1). Work is still ongoing to improve 
that assay, which is relatively difficult o perform 
and read, particularly when large numbers of iso- 
lates are tested. However, it does provide a refer- 
ence for comparison with other methods. Micro- 
dilution plate methods have been developed that 
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produce results comparable to those of the 
NCCLS method and are easier to perform and 
read (2-5). However, the reading of endpoints still 
poses problems in both the macrobroth and mi- 
crobroth assays. 
Agar gradient methods have also been devel- 
oped that appear to provide reproducible, accu- 
rate, and more easily read results. These include 
the E test (6) and disk diffusion test (7, 8). These 
assays are more practical for use in clinical abor- 
atories. In both the E test and the disk diffusion 
test, results are reproducible, the tests are easy to 
set up, they have adequate controls, and the results 
are read on a precise quantitative scale. The disk 
diffusion test has the advantages of lower mate- 
rial costs, and relatively easy to read results. 
Growth inhibition zone diameters in the disk 
diffusion test also correlate well with the NCCLS 
reference method MICs, and with the MICs deter- 
mined in the E test assay (8, 9). 
The purpose of this study was to evaluate the sus- 
ceptibility to fluconazole of a large population of 
pathogenic Candida isolates from a wide range of 
hospitals and countries using the only standardised 
disk diffusion test method available at the 
time the study was started (Unipath, Pfizer, UK). 
Materials and Methods. Forty-two hospital labor- 
atories used the agar disk diffusion test (Unipath) 
to test approximately 50 consecutively isolated 
yeast strains each, all strains being considered 
pathogens in the patients from whom they were 
obtained. A total of 2230 isolates from 23 countries 
were tested. Each yeast isolate was from a differ- 
ent patient; isolates from all types of infections and 
body sites were included in the study. Data on the 
mycological nd clinical response of fluconazole- 
treated patients were collected when possible. In- 
formation on the duration of therapy, dose of flu- 
conazole, concomitant medication, primary diag- 
nosis, underlying diseases, and other data usually 
collected in clinical trials was not considered 
relevant in this laboratory study. Three quality 
control strains of Candida albicans (Y01-09, 
Y01-108, Y01-19) were included with each batch 
of yeast isolates tested. The agar diffusion test was 
performed exactly as described by the original 
manufacturer (data on site, Pfizer, USA) using 25 
~tg fluconazole disks on 4 mm deep High Resolu- 
tion (HR) agar medium in 90 mm petri plates. The 
yeast inoculum was prepared by adjusting the den- 
sity of yeast cells in a normal saline suspension, 
using a microscope and haemocytometer, to ap- 
proximately 20 cells/mm 2 in the grid.The final cell 
density was adjusted to 4 x 107 cells/ml. After 
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Figure 1: Susceptibility to fluconazole of 1634 isolates of Candida albicans as determined by the disk diffusion test on HR 
medium incubated at 28~ The proposed breakpoints are: resistant < 18 mm; dose-dependent susceptible 18-25 mm; sus- 
ceptible >- 26 mm. 
incubation for 24 h at 28~ the diameter of the 
zone of inhibition of yeast growth around the flu- 
conazole disks was measured and recorded. 
Quality control strains were tested each day the 
clinical isolates were tested and results recorded; 
the diameter of their inhibition zones had to fall 
within the ranges specified. 
Because the MICs were not systematically deter- 
mined for these isolates, MIC correlates cannot be 
derived from these data. The proposed break- 
points for the disk diffusion test are deducted from 
statistical analysis of the inhibition zone diameters 
measured. 
Results and Discussion. The results for 1634 
Candida albicans isolates are shown in Figure 1. 
They indicate that 97.1% of the Candida albicans 
isolates were susceptible, or dose-dependent sus- 
ceptible, to fluconazole using a cut-off value of 
_> 18 mm. The isolates displayed a normal bell- 
shaped distribution with a normality value of 
0.96, mean of 33.5 mm, mode of 35 mm, and stan- 
dard deviation (SD) from the mean of 7.6 mm. 
One SD from the mean included zone diameters 
from 26 to 41 mm, and two SDs included zone dia- 
meters from 18 to 49 mm; 95% of test results were 
between two SDs. These SD values provided asta- 
tistical basis for proposing _> 26 mm and < 18 mm 
as the susceptibility and resistance breakpoints, re- 
spectively. The preliminary resistance breakpoint 
of < 18 mm, as defined in the protocol, thus re- 
mained unchanged. However, the preliminary 
susceptibility breakpoint of -> 30 mm, as defined 
in the protocol, divided the normal susceptible 
population ear the mean of the zone diameter 
measurements. The proposed breakpoints separ- 
ated the susceptible population from the more re- 
sistant population, i. e. those falling outside of two 
SD and representing 2.9% of 1634 isolates. Thus, 
97.1% of isolates were determined to be suscep- 
tible, or dose-dependent susceptible, applying in- 
terpretive criteria based on the proposed NCCLS 
breakpoints. About 8.4 % of the Candida albicans 
isolates was categorised as being dose-dependent 
susceptible, i.e. the isolates were susceptible to 
doses greater than 100 mg fluconazole daily. 
The susceptibility to fluconazole of 596 isolates 
of other Candida species is shown in Figure 2. 
As most of these isolates showed growth rates 
comparable to those of Candida albicans on HR 
medium, these tests were read after 24 hours 
of incubation at 28~ When the criteria developed 
for Candida albicans were applied to these 
isolates, 83.6 % were determined to be susceptible 
or dose-dependent susceptible. Only 16.9% were 
categorised as dose-dependent susceptible with 
inhibition zones between 18 and 25 mm; these 
isolates were susceptible to doses greater than 
100 mg fluconazole daily, except for Candida 
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Figure 2: Susceptibility to fluconazole of 596 Candida species other than Candida albicans including 139 isolates of Candi- 
da glabrata, 55 isolates of Candida krusei, and 402 isolates of other Candida species as follows: C. tropicalis (197; 6 resist- 
ant), C. parapsilosis (123; 2 resistant), C. guillermondii (22; 1 resistant), C. inconspicua (13; 1 resistant), C. famata (7; none 
resistant), C. humicola (6; none resistant), C. lusitaniae (6; 2 resistant), C. parakrusei (6; none resistant), others (22; 4 resist- 
ant). For method and breakpoints see legend to Figure 1. 
krusei isolates which were considered resis- 
tant to fluconazole regardless of the in vitro test 
result. 
Of the non-Candida albicans isolates, 32.6% 
(194/596) were Candida krusei or Candida glab- 
rata. Although only 16% (98/596) of all non-Can- 
dida albicans isolates were categorised as being re- 
sistant o fluconazole, 44% (24/55) of the Candi- 
da krusei isolates and 40% (56/139) of the 
Candida glabrata isolates were resistant (Figure 2). 
Thus, these two species represented 82% (80/98) 
of all fluconazole-resistant non-Candida lbicans 
isolates. Of 101 non-Candida albicans isolates 
categorised as dose-dependent susceptible, 17% 
were Candida krusei and 32% Candida gtabrata. 
Of the remaining 397 non-Candida lbicans iso- 
lates categorised as susceptible, only 3.5% were 
Candida krusei and 13% Candida glabrata. Thus 
the disk diffusion test breakpoints proposed for 
Candida albicans also appear to apply to these 
non-albicans pecies of Candida, although clinical 
studies and clinical experience with these isolates 
have been much less extensive than with Candi- 
da albicans (10). Candida species that do not pro- 
duce readily visible growth within the 24 hour in- 
cubation period should, for the meantime, be 
tested by a different method. 
Of the three Candida albicans quality control 
strains, Candida albicans Y01-19 (NCPF 3726) 
demonstrated the best reproducibility, 94% 
(163/174) of the inhibition zone diameter measure- 
ments falling between 15 and 21 mm. The two oth- 
er quality control strains, Y01-108 and Y01-09, 
yielded a wider range of inhibition zone diameter 
measurements, with a reproducibility of75% and 
54 %, respectively. 
Clinical relevance is an important aspect of all 
drug susceptibility est results. Limited information 
has been published for any method on the corre- 
lation between clinical or mycological responses 
and test results (7, 9, 11). Rex et al. (9, 11, 12) re- 
ported that a strong correlation existed between 
clinical outcome and fluconazole MIC using the 
NCCLS M27-T broth method to test Candida iso- 
lates, and that higher doses could be used against 
isolates with higher MICs. Isolates with MICs 
< 64 ~g/ml tended to respond well to fluconazole 
therapy, whereas those with MICs _> 64 ~tg/ml 
(and smaller zone diameters) tended to respond 
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poorly. Troillet et al. (7) also showed good corre- 
lation between zone diameter results in the flucon- 
azole disk diffusion test and the clinical and my- 
cological outcome in AIDS patients. 
The interpretive guidelines defined in this study 
protocol were preliminary and based on the lim- 
ited data available from human and animal effi- 
cacy studies of fluconazole at the time the proto- 
col was written. Since then, test results for isolates 
in rigorously controlled clinical protocols with 
strict patient entry and exclusion criteria have pro- 
vided data consistent with the results of this 
study (9,12). However, clinical efficacy protocols, 
by design, exclude many patients and pathogens. 
Consequently, they may provide a different pat- 
tern of results than the non-selected sequential 
pathogens tested in this hospital aboratory study 
which is the first to evaluate a large number and 
wide range of sequential Candida isolates from pa- 
tients with all types of hospital infections. 
The fluconazole disk diffusion method used in this 
study proved to be easy to set up and read, and 
provided test results that were reasonably repro- 
ducible in a diverse group of hospital laboratories, 
as determined by isolate and quality control 
strain performance. In particular, Candida albicans 
control strain Y01-19 (ATCC 76615/NCPF 3726) 
yielded an acceptable performance when testing 
for small zone diameters. The disk diffusion test 
appears to be a reproducible and accurate means 
of assessing the susceptibility of a wide range of 
yeasts in hospital aboratories (10). Materials are 
readily available at low cost, it is easy to establish 
controls, and the method is similar to methods 
commonly used to test bacterial isolates. Techni- 
cal difficulties were experienced in conjunction 
with the 28~ incubation temperature, which is un- 
usual for hospital incubators, the haemocytometer 
inoculum adjustment, and making HR medium. 
Subsequent to this study, improvements in the disk 
diffusion test that addressed these technical diffi- 
culties were evaluated (8); 250 Candida species 
isolates were thereby tested in parallel by the 
standard macrobroth dilution assay, fluconazole 
E test, and 25 gg fluconazole disk diffusion test 
(using RPMI  medium with 2% glucose, swab 
inoculation of an inoculum of 0.5-2.5 x 103 cfu/ml, 
incubation at 35~ for 24 and 48 h). All three 
methods were in excellent agreement. 
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Nosocomial Outbreak of 
Clostridium difficile Diarrhea 
in a Pediatric Service 
A.  Fer ron i  1, J. Merckx  2, T. Ance l le  3, 
B. P ron  1, E.  Abach in  1, E Barbut  4 , 
J. Larzu l  1, R R igau l t  2, R Berche  ], 
J.-L. Ga i l l a rd  1. 
An outbreak of nosocomial diarrhea that occurred 
in a pediatric orthopedic service between 1 Decem- 
ber 1993 and 15 April 1994 is reported. A total of 
37 patients (mean age, 9.6 years; range, 
2 months-19.3 years) were involved in the outbreak, 
including six patients with bacteriologically docu- 
mented Clostridium difficile infection. A multivari- 
ate analysis identified lincomycin treatment for at 
least three days as the only significant risk factor. 
Stool samples from four asymptomatic patients 
were also positive for Clostridium difficile and its cy- 
totoxins. Isolates from all patients belonged to se- 
rogroup C, were highly resistant o lincomycin, and 
exhibited the same restriction pattern by pulsed- 
field gel electrophoresis. The outbreak ended after 
treatment with lincomycin was discontinued and 
hygiene control measures were implemented. 
Clostridium difficile is the most common agent of 
pseudomembranous colitis and antibiotic-asso- 
ciated diarrhea (1). It has been implicated in 
many outbreaks of diarrhea affecting hospitalized 
adult patients (2, 3). Hospital acquisition of Clos- 
tridium difficile has also been demonstrated in a 
pediatric population (4, 5). However, there have 
been few reports and no epidemiological investi- 
gations of nosocomial outbreaks of Clostridium 
difficile-associated iarrhea in pediatric wards 
(6). We describe an outbreak of diarrhea in ape- 
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